Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma

References

• Pistloesi M, Rusthoven J. Malignant pleural mesothelioma: Update, current management, and newer therapeutic strategies. Chest 2004; 126: 1318–1329
   PubMedGoogle Scholar
• Curran D, Sahmoud T, Therasse P. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145–152
   PubMed Web of Science ®Google Scholar
• Alberts AS, Falkson G, Goedhals L. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527–535
   PubMed Web of Science ®Google Scholar
• Gatzemeier U. Pemetrexed in malignant pleural mesothelioma. Oncology (Huntingt) 2004; 18(13 Suppl 8)26–31
   PubMedGoogle Scholar
• Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: Past results and recent developments. Lung Cancer 2004; 45(Suppl 1)S103–S119
   Google Scholar
• Rusch V, Saltz L, Venkatraman E, Ginsburg R, McCormack P, Burt M, Markman M, Kelsen D. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12: 1156–1163
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Mentzer SJ, DeCamp M, Lynch TJ, Jr, Strauss GM. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 1993; 103(Suppl 4)377–381
   Google Scholar
• Ratto GB, Civalleri D, Esposito M, Spessa E, Alloisio A, De Cian F, Vannozzi MO. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999; 117: 759–765
   PubMed Web of Science ®Google Scholar
• De Bree E, van Ruth S, Baas P, Rutgers EJ, Van Zandwijk N, Witkamp AJ, Zoetmulder FA. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480–487
   PubMed Web of Science ®Google Scholar
• Grondin SC, Sugarbaker DJ. Malignant mesothelioma of the pleural space. Oncology (Huntingt) 1999; 13: 919–926, Discussion 926, 931–932
   PubMed Web of Science ®Google Scholar
• Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: Review of 123 patients. Cancer 1982; 49: 2431–2435
   PubMed Web of Science ®Google Scholar
• Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527–535
   PubMed Web of Science ®Google Scholar
• Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 1993; 72: 394–404
   PubMed Web of Science ®Google Scholar
• Lerner HJ, Schoenfeld DA, Matin A, Falkson G, Borden E. Malignant mesothelioma: The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52: 1981–1985
   PubMed Web of Science ®Google Scholar
• Magri MD, Veronesi A, Folodore S, De Giovanni D, Serra C, Crismancich F, Tuveri G, Nicotra M, Tommasi M, Morassut S. Epirubicin in the treatment of malignant mesothelioma: A phase II cooperative study. Tumori 1991; 77: 49–51
   PubMed Web of Science ®Google Scholar
• Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987; 71: 857–858
   PubMedGoogle Scholar
• Zider BL, Green S, Pierce HL, Roach RW, Balcerzak SP, Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 1988; 6: 223–226
   PubMedGoogle Scholar
• Planting AST, Schelens JHM, Goey SH, Van der Burg ME, De Boer-Dennert M, Stoter G, Verweij J. Weekly high-dose cisplatin in malignant mesothelioma. Ann Oncol 1994; 5: 373–374
   PubMedGoogle Scholar
• Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, Corte P, Bye P, McCaughan B. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8: 151–154
   PubMedGoogle Scholar
• Harvey VJ, Slevin ML, Ponder BA, Blackshaw AJ, Wrigley PF. Chemotherapy of diffuse malignant mesothelioma: Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984; 54: 961–964
   PubMed Web of Science ®Google Scholar
• Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: A phase II study. Br J Cancer 1992; 65: 956–960
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck J, Debruyne C, van Zandwijk N, Postmus PE, Pennucci MC, Van Breukelen F, Galdermans D, Groen H, Pinson P, Van Glabbeke M, et al. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74: 961–963
   PubMed Web of Science ®Google Scholar
• Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18: 3912–3917
   PubMed Web of Science ®Google Scholar
• Van Meerbeek JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, Van Marck EA, Lentz M, Giaccone G. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999; 85: 2577–2582
   PubMedGoogle Scholar
• Anderson MK, Krarup-Hansen A, Martensson G, Winther-Nielsen H, Thylen A, Damgaard K, Olling S, Wallin J. Ifosfamide in malignant mesothelioma: A phase II study. Lung Cancer 1999; 24: 39–43
   PubMedGoogle Scholar
• Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556–1561
   PubMed Web of Science ®Google Scholar
• Bass P. Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbine. Semin Oncol 2002; 29: 62–69
   Google Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM, Jr, Swanson SJ, Bueno R, Lukanich JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54–63, Discussion 63–65
   PubMed Web of Science ®Google Scholar
• Yoshino I, Yamaguchi M, Okamoto T, Ushijima C, Fukuyama Y, Ichinose Y, Maehara Y. Multimodal treatment for respectable epithelial type malignant pleural mesothelioma. W J Surg Oncol 2004; 2: 11–14
   PubMedGoogle Scholar
• Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004; 22: 3451–3457
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Casale C, Colistro F, Benassi M, Lovisolo G, Begnozzi L. One versus four heat treatments in combination with radiotherapy in metastatic mammary carcinoma. Int J Radiat Oncol Biol Phys 1991; 21: 1569–1574
   PubMed Web of Science ®Google Scholar
• Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and hypothesis. Cancer 1977; 37: 2637–2648
   Google Scholar
• Song CW. Effect of local hyperthermia and blood flow and microenvironment: A review. Cancer Res 1984; 44(Suppl 10)4721S–4730S
   Google Scholar
• Rusch VW, Niedzwiecki D, Tao Y, Menendez-Botet C, Dnistrian A, Kelsen D, Saltz L, Markman M. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 1992; 10: 1001–1006
   PubMed Web of Science ®Google Scholar
• Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am 1989; 27: 621–627
   PubMed Web of Science ®Google Scholar